| abstract |
The present invention is directed to sustained release matrix formulations that can be directly driven into tablets, including niacin, release-delaying agents, and other excipients. The resulting tablets of the present invention show desirable release properties and reduction in severity, duration and incidence of skin flushing generally associated with niacin regimens. |